Pay in 4 interest-free payments of $6.78 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
PMID: 77 MallJNaseemNHaiderMFRahmanMAKhanSSiddiquiSN
[2] [3] GLP-1 medications reduced major adverse cardiovascular events by 20% in the SELECT trial, with benefits extending beyond weight loss alone
Critically, these events were most prevalent during initiation/escalation of therapy and declined substantially over time
hypoglycemia risk if on insulin) eGFR below 30 (tirzepatide exclusion in SURMOUNT-5) Recent cardiac event or NYHA Class IV heart failure Active suicidal ideation (trials excluded PHQ-9 scores of 15 or above) If your tirzepatide vs semaglutide question is pure weight loss without comorbidities, tirzepatide wins on the numbers
Prescribing restrictions based on BMI thresholds or weight-loss targets may not be appropriate, as patients such as those included in our study (with overweight or obesity) might benefit regardless of weight-loss response.
This is according to new research presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting by Elizabeth McDonald, a professor of radiology in Penns Perelman School of Medicine and a practicing breast radiologist at Penns Abramson Cancer Center
US$ 27.32
US$ 28.88
US$ 23.00
